is ghk cu wada banned WADA's 2026 Prohibited List now in force We have received an uptick

For a 5 mg dose, you would inject 100 units (1.00 mL)

Since its posting, the video has garnered an impressive 800K views, 79K likes, 27K shares, 33K bookmarks, and over 3K comments

Hypothetical Conservative Combination Protocol A conservative approach to combining these peptides would likely involve: Phase 1: Tirzepatide Establishment (Weeks 1-12) Week 1-4: Tirzepatide 2.5 mg weekly Week 5-8: Tirzepatide 5 mg weekly Week 9-12: Tirzepatide 7.5 mg weekly Cagrilintide: None (establish baseline tolerance) Phase 2: Cagrilintide Introduction (Weeks 13-20) Week 13-16: Tirzepatide 7.5 mg + Cagrilintide 0.6 mg weekly Week 17-20: Tirzepatide 7.5 mg + Cagrilintide 1.2 mg weekly Phase 3: Optimization (Week 21+) Tirzepatide 10-12.5 mg + Cagrilintide 2.4 mg weekly Adjust based on tolerance and response "The key principle when considering any peptide combination is sequential introduction with careful monitoring of tolerability markers, particularly gastrointestinal symptoms that could compound across mechanisms." This theoretical framework prioritizes safety through staged introduction, though actual clinical protocols would require medical supervision and monitoring

The dose-response data show a weight effect that flattens toward the top of the range alongside dose-dependent gastrointestinal adverse events, which is consistent with a tolerability-driven choice but that reading is an inference drawn here, not a documented rationale, and Novo Nordisk has published no dose-selection statement

The compound helps grow strong tissue fibers and moves healing cells directly to the injury